Cotrimoxazole use is associated with lower total and non-high density lipoprotein cholesterol among people with HIV: a cross-sectional study

Table 2 Comparison of lipid parameters between PWH on currentcotrimoxazole prophylaxis and those who are not

See More Lipid parameter	Total N = 395	PWH on cotrimoxazole n = 100	PWH not using cotrimoxazole n = 295	p-value
Total Cholesterol (mmol/l), mean (SD)	4.5 (1.0)	4.2 (1.0)	4.6 (1.0)	< 0.001
LDL-Cholesterol (mmol/l), mean (SD)	2.9 (0.9)	2.7 (0.9)	3.0 (0.9)	0.002
HDL-Cholesterol (mmol/l), mean (SD)	1.0 (0.5)	1.1 (0.5)	1.0 (0.5)	0.093
Non-HDL cholesterol (mmol/l), mean (SD)	3.5 (1.0)	3.1 (1.0)	3.6 (1.0)	< 0.001
Triglycerides (mmol/l), mean (SD)	1.5 (1.0)	1.5 (1.2)	1.5 (0.9)	0.700
VLDL-cholesterol (mmol/l), median (IQR)	0.26 (0.2–0.3)	0.26 (0.2–0.3)	0.27 (0.2–0.4)	0.701
Atherogenic index of plasma (AIP), mean (SD)	0.4 (0.6)	0.3 (0.6)	0.4 (0.6)	0.061
Elevated total cholesterol* (n = 390), n (%)	117 (30.0)	21 (21.2)	96 (33.0)	0.027
Elevated LDL-c* (n = 390), n (%)	34 (8.7)	6 (6.1)	28 (9.6)	0.280
Elevated non-HDL-c (n = 390), n (%)	108 (27.7)	11 (11.1)	97 (33.3)	< 0.001
Low HDL-c* (n = 390), n (%)	280 (71.8)	61 (61.6)	219 (75.3)	0.009
Hypertriglyceridemia* (n = 390), n (%)	105 (26.9)	25 (25.3)	80 (27.5)	0.660
Elevated AIP, n (%) (n = 390)	259 (66.4)	59 (59.6)	200 (68.7)	0.097

LDL low density lipoprotein, HDL high density lipoprotein, AIP atherogenic index of plasma, VLDL-c very low density lipoprotein cholesterol, SD standard deviation, IQR interquartile range
*Elevated total cholesterol (> 5.0 mmol/L), high LDL-c (> 4.14 mmol/L), high triglycerides (≥ 1.7 mmol/L), or low HDL-c (< 1.03 mmol/L for males and < 1.29 mmol/L for females

ISSN: 1476-511X